23 August 2024 - NICE has published final evidence-based recommendations on the use of risankizumab (Skyrizi) for the treatment of adults with moderately to severely active ulcerative colitis.

Risankizumab is recommended as an option for the treatment of adults with moderately to severely active ulcerative colitis when conventional or biological treatment cannot be tolerated, or the condition has not responded well enough or has lost response to treatment, only if a tumour necrosis factor (TNF) alfa antagonist has not worked (that is the condition has not responded well enough or has lost response to treatment), or cannot be tolerated or is not suitable.

Read NICE technology appraisal guidance